Fertility, Market size estimations - PowerPoint PPT Presentation

About This Presentation
Title:

Fertility, Market size estimations

Description:

24136.00 24572.00 30518.00 ... – PowerPoint PPT presentation

Number of Views:88
Avg rating:3.0/5.0
Slides: 29
Provided by: Mass71
Category:

less

Transcript and Presenter's Notes

Title: Fertility, Market size estimations


1
Swedish - American Life Science Summit
Stockholm August 20, 2009 Magnus Nilsson, CEO
2
Agenda
  • Company background
  • Market presence and growth
  • Product/therapy areas
  • Outlook 2009

2
3
Vitrolife a global life science company
  • A global life science company (Bio-Med Tech).
    Main sites in Gothenburg and Denver, Colorado
  • Developing, manufacturing and selling nutrient
    solutions (media) and instruments for fertility
    treatments and lung transplantations.
  • Growing and profitable business founded in 1994.
  • Approx 160 employees.
  • Sales in more than 85 countries. Local presence
    Nordic countries, US, Canada, Italy, Benelux,
    Austria, Germany, China, Japan, Australia, France
  • Listed on the OMX Nordic Exchanges Nordic Small
    Cap list since 2001.

Company Background
4
Our Vision
  • Vitrolife strives to be the leading supplier
    of media and other advanced disposables, used by
    hospitals and laboratories performing fertility
    treatment and other therapies where cells or
    tissues are used or are a part of the therapy.

4
Company Background
5
Vitrolife Strategy
5
Company Background
6
A Process organisation to reflect the value
chain
Purchasing
Production
QC
Sales
Order
Distribution
Product idea valuation
Product development
Marketing
Supporting Processes Quality Assurance
Finance/Information IT Human Resources
Administration
6
Company Background
7
Vitrolife Reaching the global market
New offices in China and Japan 2009
7
Market presence and growth
8
Sales by region rolling 12 months
8
Market presence and growth
9
Sales and growth rate 2009
9
Market presence and growth
10
Sales and growth rate 2009 - Fertility
Share of sales of Vitrolife
Growth rate for Vitrolife
Growth rate for Vitrolife
Regional share of global cycles
1.0 million cycles performed world wide per
year
10
Market presence and growth
11
Highlights of 2009
  • Sales first half year 23
  • Increased investment in RD and marketing
  • Fertility Strong development in Asia, Europe and
    Middle East
  • Transplantation Positive progress for the
    clinical study in Canada for STEEN Solution
  • Successfull start up of the new offices in Asia
  • Dividend 0.40 SEK/share paid out
  • EBITDA 28,4 of sales
  • Operating margin 14,4

Market presence and growth
12
Key Financials Investing in growth for the future
SEKm
14 of Sales invested in RD activities
Investing in growth
12
Market presence and growth
13
Product areas - a genius combination
TRANSPLANTATION
FERTILITY
  • Customers/markets
  • Public clinics
  • 200 Lung transpl clinics / 2000 all
    transplantations
  • Subsidized
  • 3000 Lungs/ 50000 all transplantations
  • Customers/markets
  • Private and public clinics/ specialized
    laboratories
  • 3000 clinics
  • Partly subsidized
  • 1 million clin. IVF treatm.
  • Customers/markets
  • Public specialized laboratories /research
    institutions and private companies
  • 400 institutions / 150 companies
  • Subsidized private
  • Research, in clinics 2-5 years

13
Product /Therapy areas
14
Fertility Competitive advantage
FERTILITY
  • A complete range of advanced clinical products
  • Regulatory approval
  • CE mark
  • FDA 510(k)
  • State of the art production facilities
  • Industry leading QC
  • Global market reach
  • External collaboration with the leading scientist
  • New unique needle for the collection of human
    oocytes, Swemed Sense, recently launched and
    approved for sales in Europe
  • Potential market estimated to EUR 50 million

14
Product /Therapy areas
15
History of Innovations
FERTILITY
Beyond HSA Recombinant media r-S1/ r-S2
First sequential media G1/ G2 v. 2
New technique -follicle aspiration needle with
ultrasound probe
Pharmaceutical-grade media IVF-50
Closer to NatureGIII Series v.3
ICSI Medium
1983
1994
1995
1998
2001
2002
Breakthrough Innovations
Unique aspiration needle SWEMED Sense
Acquisition of SWEMED lab
EmbryoGlueImplantation promoting medium
GIII Series CE marked
Ultrarapid vitrification
15
2004
2003
2005
2006
2007
2008
Product /Therapy areas
16
Product portfolio development
FERTILITY
  • Strategy Portfolio expansion through RD and
    acquisitions to optimize market synergies

16
Product /Therapy areas
17
Stem Cell cultivation
  • Products for human embryo stem cells and cryo
    preservation of stem cells
  • State of the art production facilities
  • Industry leading QC
  • Cooperation with leading scientist

In VitroHes researchers can successfully grow
human stem cells and maintain pluri potency
17
Product /Therapy areas
18
Giant market expectations in cell therapy
Source Jain Pharmatech
18
Product /Therapy areas
19
Cell Therapy Situation analysis
  • Clinical applications for MSC, HSC, CBSC, FNSC
  • gt3 years before therapies based on hESC reach
    clinic due to
  • Difficulties to control differentiation
  • Scaling up production
  • Ethically controversial
  • Regulatory authorities

19
Product /Therapy areas
20
Stem cell culture media Regulatory
  • Harmonisation of regulatory requirements and a
    long term view is a need for a safe treatment
  • US
  • Regulated by FDA/ CBER
  • Classified as Class 1 Medical Device, exempted
    from 510(k)
  • EU
  • Classified as non Medical Device
  • To be produced according to GMP

20
Product /Therapy areas
21
Stem Cell Cultivation Focus areas
  • Increase focus on development of new clinical
    grade stem cell media together with our
    partners.
  • Fulfill the clinical requirements as set out in
    other areas

Product /Therapy areas
22
Transplantation the new way
TRANSPLANTATION
  • The new method radically increases the
    availability of organs for transplantation
  • Pioneering lung perfusion system (ex vivo and at
    37ºC)
  • Clinical trial in North America of Steen
    Solution
  • Innovative equipment for organ evaluation ex vivo
  • Development of perfusion systems for other organs
  • Preclinical trials with other organs e.g. liver,
    heart

22
Product /Therapy areas
23
STEEN Solution - Focus Area
TRANSPLANTATION
  • Finish clinical studies in North America and
    apply for marketing authorization for Steen
    Solution in the U.S. Clinical results so far
    very promising.
  • 25 lungtransplantations performed in clinic so
    far
  • Continue launch of STEEN Solution in Europe by
    training and education in the STEEN Solution
    method to get market acceptance
  • Developing of and clinical trials with additional
    products needed for a lung-assessment with Steen
    Solution .

Product /Therapy areas
24
Vitrolife STEEN SolutionTM
TRANSPLANTATION
Problem
STEEN Solution
Advantage
  • gt70 of donated organs are not used
  • Too few organs to transplant
  • Short of time, a maximum of 8-12 hours outside
    the body
  • Patients die while waiting for organs
  • Functional testing
  • Large number of potential donors (including
    donation after cardiac death)
  • Maximum time gt24 hours outside the body
  • More patients can be provided with new lungs
  • More organs can be used
  • More organs available for transplantation
  • More organs can be used in time (lower cost)
  • Fewer deaths caused by lack of organs

? ? ? ?
? ? ? ?
Product /Therapy areas
25
Vitrolife STEEN SolutionTM
TRANSPLANTATION
  • Before STEEN Sol.
  • Costs for products per evaluation (SEK) ca
    10.000 gt 30.000
  • Potential number of transplantations ca 3.000 gt
    20.000
  • Market potential, lungs only (SEK million) ca
    35 gt 600
  • Including research market
  • Approved in Europe 2006, and in Australia 2008.
  • The method is also being developed for other
    organs, e.g. liver.

Product /Therapy areas
26
Outlook 2009
  • Continued execution of main strategy
  • Establish direct sales on all major markets
    covering 80 of all treatments
  • Exploit market synergies with broader product
    portfolio through development and/or acquisitions
  • Increase gross margin through continuous
    improvement of operations
  • One major new product launch in Product Area
    Fertility
  • Support launch of STEEN Solution in Europe and
    prepare for market introduction in USA and Canada
  • Strong RD focus with gradually increasing
    efforts in Transplantation and Stem Cell
    Cultivation
  • Maintain profitable growth and operational strong
    cash flow

Outlook 2009
27
With sustainable profit cash flow
reaching the global market
investing in growth
for the future
28
(No Transcript)
Write a Comment
User Comments (0)
About PowerShow.com